Vaginal Dryness / Genitourinary Syndrome of Menopause (GSM) Treatment
Covered by Aetna in California

FIRST-LINE LOCAL ESTROGEN: Estradiol vaginal cream 0.01% (conjugated estrogen or estradiol) 2–4g intravaginally daily × 2 weeks (loading dose), then 1g twice weekly for maintenance — per ACOG Practice Bulletin and NAMS 2023 Hormone Therapy Position Statement; acts locally on vaginal epithelium with minimal systemic absorption at low doses. OR estradiol vaginal insert 10mcg (generic Vagifem) inserted daily × 14 days then twice weekly for maintenance. Both formulations restore vaginal pH, improve vaginal epithelial maturation index, and relieve dryness and dyspareunia.

Estradiol vaginal ring (Estring) 7.5mcg/day inserted every 3 months — convenient for patients who prefer infrequent administration; Tier 2–3 on Aetna CA. Ospemifene 60mg orally once daily (SERM, non-estrogen) — FDA-approved for moderate-to-severe dyspareunia and vaginal dryness due to menopause; non-formulary on standard Aetna CA but valuable for patients with contraindications to estrogen including history of estrogen-receptor-positive breast cancer; self-pay typically $200–$300/month. Prasterone (DHEA) 6.5mg vaginal insert (Intrarosa) once nightly — non-estrogen alternative, converted locally to estrogen and androgens. Polycarbophil-based vaginal moisturizers (Replens, Applied nightly OTC) and silicone-based lubricants for symptomatic relief without prescription.

Yes — vaginal estradiol cream (estradiol 0.01%) and generic estradiol vaginal inserts 10mcg are Tier 1–2 on Aetna CA, typically $15–$40/month. Systemic estradiol 1mg tablets and estradiol transdermal patches are Tier 1 generics (~$10–$30). Ospemifene (Osphena) is Non-Formulary on most Aetna CA standard plans — the covered alternative is local vaginal estradiol. Patients with insurance-covered brands can check their specific Aetna CA plan formulary for estrogen ring and DHEA insert coverage.

Per ACOG and the North American Menopause Society (NAMS 2023), low-dose vaginal estrogen therapy is safe and appropriate for most postmenopausal women with GSM, including women with a history of breast cancer in many cases (in consultation with their oncologist). Systemic estrogen absorption from low-dose vaginal preparations is minimal — serum estradiol levels typically remain within postmenopausal range. Progestogen co-administration is NOT required with low-dose vaginal estrogen in women with an intact uterus (unlike systemic estrogen). Women with a history of estrogen-receptor-positive breast cancer on aromatase inhibitors should discuss ospemifene or vaginal DHEA (prasterone) with their oncologist before initiating any vaginal hormonal therapy. TDMD does not prescribe systemic hormone therapy for complex cardiovascular or cancer risk scenarios — those require in-person specialist evaluation.

This is one of the most important clinical nuances in menopause management. Low-dose vaginal estradiol (10mcg inserts, 0.01% cream) produces minimal systemic absorption — serum estradiol levels remain in the postmenopausal range — and is generally considered safe for breast cancer survivors who are not on aromatase inhibitors, based on ACOG Clinical Consensus 2021 and NAMS guidance. However, women on aromatase inhibitors (anastrozole, letrozole, exemestane) for ER-positive breast cancer should consult their oncologist before any vaginal hormonal therapy, because even minimal estradiol absorption could theoretically reduce aromatase inhibitor efficacy. For these patients, ospemifene (a SERM) or vaginal DHEA (prasterone) are non-estrogen alternatives, and Dr. Bhavsar will recommend OB or oncology consultation rather than prescribing directly.

Ospemifene (Osphena) 60mg is listed as Non-Formulary on the standard Aetna CA commercial plan — the covered alternatives are low-dose vaginal estradiol products, which are equally or more effective for most patients with GSM. If you have a specific reason ospemifene is clinically preferable (e.g., estrogen contraindication from ER-positive breast cancer history, or strong preference for an oral non-hormonal option), Dr. Bhavsar can document medical necessity to support a formulary exception request. Alternatively, ospemifene is available for self-pay at approximately $200–$300/month without insurance — a higher cost than covered vaginal estradiol but an appropriate choice for selected patients.

No — not for low-dose local vaginal estradiol. Progestogen co-administration is required with systemic estrogen in women with an intact uterus to prevent endometrial hyperplasia. Low-dose vaginal estradiol preparations (10mcg inserts, 0.01% cream) deliver estrogen locally with minimal systemic absorption and do not significantly stimulate the endometrium. Per ACOG and NAMS guidance, progestogen is not routinely required when low-dose vaginal estradiol alone is used for GSM. However, if systemic estrogen is added for hot flashes or other menopausal symptoms in a woman with an intact uterus, progestogen must accompany it — a more complex scenario Dr. Bhavsar manages at the visit.

Dr. Bhavsar can evaluate straightforward systemic menopausal hormone therapy (oral estradiol tablets or transdermal estradiol patches ± progesterone) for healthy perimenopausal and postmenopausal women without complex cardiovascular risk, recent VTE, active liver disease, or active breast cancer. Systemic HRT requires a more comprehensive risk assessment than local vaginal estrogen — cardiovascular disease history, VTE risk, and cancer history are reviewed at the visit. Women with complex comorbidities or those considering combined systemic HRT after breast cancer are referred to in-person gynecology or menopause specialist consultation. Oral estradiol 1mg and transdermal estradiol patches are Tier 1 generics on Aetna CA, typically $10–$30/month.

Yes. Aetna commercial plans cover telehealth visits for Vaginal Dryness / Genitourinary Syndrome of Menopause (GSM) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your vaginal dryness treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your vaginal dryness treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.